Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / Cramer 5-marker panel for ovarian cancer

Cramer 5-marker panel for ovarian cancer

Basics

Attributes

QA State: Curated
Short Name:

The PLCO phase III specimens (test half) revealed marker panels produced only marginal improvement over CA 125 alone and, in some case, worse performance. Besides searching for new markers, some ways to improve detection might include: 1) Add epidemiologic variables, and 2) Add in prior markers values.

Panel Details

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: Three
QA State: Curated

The PLCO accepted the phase II reports (SPORE/EDRN/PLCO Ovarian Validation Study) and sent identical sets to the assay sites. Each set included sera for cases most proximate to the diagnosis of ovarian cancer which (on average) was about 9 months prior. There were 951 controls matched by age and timing of specimen collection including 475 general population controls, 238 with false positive CA 125, and 238 with family history of breast or ovarian cancer. 90 quality control specimens were also included. Investigators tested their markers and marker panels blinded to the status of the cases. PLCO unblinded the data in stages to allow further algorithm development.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Organs

No associated resources found.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html